Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Merck & Co. got a lukewarm “neutral” rating from Citigroup, along with a price target drop from $115 to $84. Other analysts ...

We recently published a list of the Best Income Stocks to Invest in Now. In this article, we are going to take a look at ...

We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where Merck ...

While Merck's shares declined by 3% over the last month, this shift aligns with the flat market performance, ...

We recently compiled a list of the 10 Most Profitable Cheap Stocks to Buy Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other most ...

Merck is facing an awkward encore as one of the worst-performing blue chip stocks in 2025, sliding 23.3% year-to-date.

Shares fell after the company cut its full-year guidance on the back of challenging macroeconomic conditions and ...

Merck KGaA reduced its outlook for sales and profit growth this year, citing the impact of a weak US dollar and uncertainty ...

MERCK & CO INC (MRK) is a large-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 100% based on the firm’s underlying fundamentals and the stock’s valuation.

We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now. In this article, we are ...